Pelvic exenteration for advanced and recurrent malignancy.

PubWeight™: 0.86‹?›

🔗 View Article (PMID 20512493)

Published in World J Surg on September 01, 2010

Authors

Evita Zoucas1, Sven Frederiksen, Marie-Louise Lydrup, Wiking Månsson, Pelle Gustafson, Per Alberius

Author Affiliations

1: Department of Surgery, University of Lund, Lund, Sweden. EZoucas@aol.com

Associated clinical trials:

Surgery for Locally Advanced Colon Cancer: is it Worth it? A Multicenter Retrospective Analysis. (LACC) | NCT04646772

Articles cited by this

Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol (1998) 9.89

Guidelines 2000 for colon and rectal cancer surgery. J Natl Cancer Inst (2001) 5.68

Rectus flap reconstruction decreases perineal wound complications after pelvic chemoradiation and surgery: a cohort study. Ann Surg Oncol (2005) 1.92

Pelvic resection of recurrent rectal cancer: technical considerations and outcomes. Dis Colon Rectum (1999) 1.30

Treatment strategy for locally recurrent rectal cancer. Jpn J Clin Oncol (2006) 1.24

Quality of life and functional outcome following anterior or abdominoperineal resection for rectal cancer. Eur J Surg Oncol (2005) 1.21

Curative potential of multimodality therapy for locally recurrent rectal cancer. Ann Surg (2003) 1.17

Total pelvic exenteration with distal sacrectomy for fixed recurrent rectal cancer in the pelvis. Dis Colon Rectum (2004) 1.17

Total pelvic exenteration: the Albert Einstein College of Medicine/Montefiore Medical Center Experience (1987 to 2003). Gynecol Oncol (2006) 1.17

Treatment of locally recurrent rectal carcinoma--results and prognostic factors. Int J Radiat Oncol Biol Phys (1998) 1.09

Locally recurrent rectal cancer: predictors and success of salvage surgery. Dis Colon Rectum (2001) 1.08

Pelvic exenteration and sacral resection for locally advanced primary and recurrent rectal cancer. Dis Colon Rectum (2002) 1.04

Curative surgery for local pelvic recurrence of rectal cancer. Dig Surg (2003) 1.03

Total pelvic exenteration for primary and recurrent malignancies. World J Surg (2009) 1.02

Phase II study of irinotecan and cisplatin as first-line chemotherapy in advanced or recurrent cervical cancer. Oncology (2000) 1.02

Extensive surgery after high-dose preoperative chemoradiotherapy for locally advanced recurrent rectal cancer. Dis Colon Rectum (2000) 0.98

Use of transpelvic rectus abdominis musculocutaneous flap for anal cancer salvage surgery. Br J Surg (2003) 0.96

Improvements in pelvic exenteration: factors responsible for reducing morbidity and mortality. Ann Surg Oncol (1998) 0.96

Results of an aggressive approach to resection of locally recurrent rectal cancer. Ann Surg Oncol (2006) 0.95

Contemporary outcomes of total pelvic exenteration in the treatment of colorectal cancer. Dis Colon Rectum (2003) 0.95

Pain and quality of life after treatment in patients with locally recurrent rectal cancer. J Clin Oncol (2002) 0.95

Sacral resection for recurrent rectal cancer: analysis of morbidity and treatment results. Dis Colon Rectum (2006) 0.94

Pelvic exenteration affords safe and durable treatment for locally advanced rectal carcinoma. Ann Surg Oncol (2007) 0.93

Quality of life and cost effectiveness analysis of therapy for locally recurrent rectal cancer. Dis Colon Rectum (2000) 0.93

Total pelvic exenteration. A 50-year experience at the Ellis Fischel Cancer Center. Arch Surg (1994) 0.91

Quality of life after pelvic exenteration. Gynecol Oncol (2004) 0.90

Outcome of total pelvic exenteration for locally recurrent rectal cancer. Hepatogastroenterology (2003) 0.89

Major complications of urinary diversion after pelvic exenteration for gynecologic malignancies: a 23-year mono-institutional experience in 124 patients. Gynecol Oncol (2004) 0.87

Radiotherapy alone in the curative treatment of rectal carcinoma. Lancet Oncol (2003) 0.84

Prognostic factors affecting oncologic outcomes in patients with locally recurrent rectal cancer: impact of patterns of pelvic recurrence on curative resection. Langenbecks Arch Surg (2008) 0.83

Qualitative assessment of patient experiences related to extended pelvic resection for rectal cancer. J Surg Oncol (2006) 0.82

Clinical outcome in patients with complete pathologic response (pT0) to preoperative irradiation/chemo-irradiation operated for locally advanced or locally recurrent rectal cancer. J Surg Oncol (2005) 0.82

Composite abdominosacral resection for recurrent rectal cancer. Br J Surg (2009) 0.81

Predictors of successful salvage surgery for local pelvic recurrence of rectosigmoid colon and rectal cancers. Surg Today (2007) 0.75

Detubularized right colonic reservoir with intussuscepted ileal nipple valve or stapled ileal ("Lundiana") outlet. Clinical and urodynamic results in a prospective randomized study. World J Urol (1996) 0.75

Ipsilateral ileal conduit placement at vertical rectus abdominis myocutaneous flap donor site in pelvic exenteration. Dis Colon Rectum (2006) 0.75

Articles by these authors

Should all patients with non-muscle-invasive bladder cancer receive early intravesical chemotherapy after transurethral resection? The results of a prospective randomised multicentre study. Eur Urol (2009) 2.80

The value of the UroVysion assay for surveillance of non-muscle-invasive bladder cancer. Eur Urol (2007) 2.77

A molecular taxonomy for urothelial carcinoma. Clin Cancer Res (2012) 2.37

MiRNA expression in urothelial carcinomas: important roles of miR-10a, miR-222, miR-125b, miR-7 and miR-452 for tumor stage and metastasis, and frequent homozygous losses of miR-31. Int J Cancer (2009) 2.06

Combined gene expression and genomic profiling define two intrinsic molecular subtypes of urothelial carcinoma and gene signatures for molecular grading and outcome. Cancer Res (2010) 1.99

Injury is a major inducer of epidermal innate immune responses during wound healing. J Invest Dermatol (2009) 1.87

Prevention and management of complications following radical cystectomy for bladder cancer. Eur Urol (2010) 1.57

Integrated genomic and gene expression profiling identifies two major genomic circuits in urothelial carcinoma. PLoS One (2012) 1.56

Treatment delay and prognosis in invasive bladder cancer. J Urol (2005) 1.53

Quality of life after cystectomy and urinary diversion: an evidence based analysis. J Urol (2005) 1.53

NFAT regulates the expression of AIF-1 and IRT-1: yin and yang splice variants of neointima formation and atherosclerosis. Cardiovasc Res (2011) 1.42

Clinical course of nonvisceral soft tissue leiomyosarcoma in 225 patients from the Scandinavian Sarcoma Group. Cancer (2007) 1.36

Fine-needle aspiration of neurilemoma (schwannoma). A clinicocytopathologic study of 116 patients. Diagn Cytopathol (2006) 1.29

Novel blocker of NFAT activation inhibits IL-6 production in human myometrial arteries and reduces vascular smooth muscle cell proliferation. Am J Physiol Cell Physiol (2006) 1.29

Tiling resolution array CGH and high density expression profiling of urothelial carcinomas delineate genomic amplicons and candidate target genes specific for advanced tumors. BMC Med Genomics (2008) 1.24

A systematic study of gene mutations in urothelial carcinoma; inactivating mutations in TSC2 and PIK3R1. PLoS One (2011) 1.21

Inadequate timing of prophylactic antibiotics in orthopedic surgery. We can do better. Acta Orthop (2009) 1.21

Liposarcoma: outcome based on the Scandinavian Sarcoma Group register. Cancer (2008) 1.11

DNA methylation analyses of urothelial carcinoma reveal distinct epigenetic subtypes and an association between gene copy number and methylation status. Epigenetics (2012) 1.07

Core-needle biopsy performed by the cytopathologist: a technique to complement fine-needle aspiration of soft tissue and bone lesions. Cancer (2005) 1.04

Toward a molecular pathologic classification of urothelial carcinoma. Am J Pathol (2013) 1.03

Surgery for metastatic lesions of the femur: good outcome after 245 operations in 216 patients. Injury (2007) 1.02

Lymph node metastasis in bladder cancer. Eur Urol (2005) 1.02

Assessment of the clinical and molecular impact of different cytogenetic subgroups in a series of 272 lipomas with abnormal karyotype. Genes Chromosomes Cancer (2007) 1.01

Bladder cancers respond to intravesical instillation of HAMLET (human alpha-lactalbumin made lethal to tumor cells). Int J Cancer (2007) 1.00

Distinct mitotic segregation errors mediate chromosomal instability in aggressive urothelial cancers. Clin Cancer Res (2007) 0.99

Intraoperative sentinel node detection improves nodal staging in invasive bladder cancer. J Urol (2006) 0.94

A novel fusion gene, SS18L1/SSX1, in synovial sarcoma. Genes Chromosomes Cancer (2003) 0.93

Diagnostic delay and prognosis in invasive bladder cancer. Scand J Urol Nephrol (2003) 0.92

Improved prognostication in soft tissue sarcoma: independent information from vascular invasion, necrosis, growth pattern, and immunostaining using whole-tumor sections and tissue microarrays. Hum Pathol (2005) 0.92

Tissue microarray based analysis of prognostic markers in invasive bladder cancer: much effort to no avail? Urol Oncol (2007) 0.90

Incontinent urinary diversion. BJU Int (2008) 0.90

Timing of preoperative antibiotics for knee arthroplasties: Improving the routines in Sweden. Patient Saf Surg (2011) 0.90

Cytologic features of primary, recurrent, and metastatic dermatofibrosarcoma protuberans. Cancer (2002) 0.90

Recurrent and multiple bladder tumors show conserved expression profiles. BMC Cancer (2008) 0.89

Fine-needle aspiration of soft tissue leiomyosarcoma: an analysis of the most common cytologic findings and the value of ancillary techniques. Diagn Cytopathol (2006) 0.87

Patient-assessed outcomes in Swedish and Egyptian men undergoing radical cystectomy and orthotopic bladder substitution--a prospective comparative study. Urology (2007) 0.87

Time dependence of prognostic factors for patients with soft tissue sarcoma: a Scandinavian Sarcoma Group Study of 338 malignant fibrous histiocytomas. Cancer (2004) 0.86

Can tissue microarray-based analysis of protein expression predict recurrence of stage Ta bladder cancer? Scand J Urol Nephrol (2011) 0.86

Microbial flora in ileal and colonic neobladders. Eur Urol (2004) 0.84

Quality of life in patients with bladder cancer. Urol Oncol (2005) 0.84

Prospective study of transitional cell carcinoma in the prostatic urethra and prostate in the cystoprostatectomy specimen. Incidence, characteristics and preoperative detection. Scand J Urol Nephrol (2007) 0.83

Long-term follow-up after radical cystectomy with emphasis on complications and reoperations: a Swedish population-based survey. Scand J Urol Nephrol (2011) 0.83

A population-based study of patterns of care for muscle-invasive bladder cancer in Sweden. Scand J Urol Nephrol (2009) 0.82

Preoperative staging of locally advanced bladder cancer before radical cystectomy using 3 tesla magnetic resonance imaging with a standardized protocol. Scand J Urol (2012) 0.82

Demonstration of mitochondrial oestrogen receptor beta and oestrogen-induced attenuation of cytochrome c oxidase subunit I expression in human periodontal ligament cells. Arch Oral Biol (2007) 0.81

Cytogenetic aberrations and their prognostic impact in chondrosarcoma. Genes Chromosomes Cancer (2002) 0.80

Gene expression demonstrates increased resilience toward harmful inflammatory stimuli in the proliferating epidermis of human skin wounds. Exp Dermatol (2010) 0.80

Molecular cytogenetic characterization of an ins(4;X) occurring as the sole abnormality in an aggressive, poorly differentiated soft tissue sarcoma. Virchows Arch (2005) 0.80

Should tumor depth be included in prognostication of soft tissue sarcoma? BMC Cancer (2003) 0.80

Hospital costs associated with surgical morbidity after elective colorectal procedures: a retrospective observational cohort study in 530 patients. Patient Saf Surg (2014) 0.80

Urothelial carcinoma in the prostatic urethra and prostate: current controversies. Expert Rev Anticancer Ther (2007) 0.80

Mucosal host responses to bacteriuria in colonic and ileal neobladders. Eur Urol (2006) 0.79

DNA ploidy in soft tissue sarcoma: comparison of flow and image cytometry with clinical follow-up in 93 patients. Cytometry (2002) 0.79

Impact of hospital volume on local recurrence and distant metastasis in bladder cancer patients treated with radical cystectomy in Sweden. Scand J Urol (2013) 0.79

The value of bladder mapping and prostatic urethra biopsies for detection of carcinoma in situ (CIS). BJU Int (2011) 0.78

Extended lymph node dissection in patients with urothelial cell carcinoma of the bladder: can it make a difference? World J Urol (2009) 0.78

Urinary diversion after cystectomy for bladder cancer: a population-based study in Sweden. Scand J Urol Nephrol (2010) 0.78

The rationale behind recommendations for follow-up after urinary diversion: an evidence-based approach. Scand J Urol Nephrol (2007) 0.77

A convenient method for local drug administration at predefined sites in the entire gastrointestinal tract: experiences from 13 phase I studies. Eur J Pharm Sci (2007) 0.77

Evidence-based urology--a utopia? Eur Urol (2004) 0.75

[Weight loss is the best treatment in obesity and obstructive sleep apnea syndrome]. Lakartidningen (2008) 0.75

The epidermal growth factor receptor is a regulator of epidermal complement component expression and complement activation. J Immunol (2014) 0.75

Re: Richard J. Sylvester, Willem Oosterlinck. An immediate instillation after transurethral resection of bladder tumor in non-muscle-invasive bladder cancer: has the evidence changed? Eur Urol 2009;56;43-5. Eur Urol (2009) 0.75

Working capacity and well-being after radical cystectomy with continent cutaneous diversion. Eur Urol (2006) 0.75

[In Process Citation]. Lakartidningen (2015) 0.75

Functional results after orthotopic bladder substitution: a prospective multicentre study comparing four types of neobladder. Scand J Urol (2013) 0.75

Chairmen's summary. Scand J Urol Nephrol Suppl (2008) 0.75

[In Process Citation]. Lakartidningen (2015) 0.75

Urostomy and health-related quality of life in patients with lower urinary tract dysfunction. Scand J Urol (2014) 0.75

The importance of being grade 3: WHO 1999 versus WHO 2004 pathologic grading. Eur Urol (2012) 0.75

[Neurologic symptoms in endoscopy. The first known Swedish case of cerebral air embolization during gastroscopy]. Lakartidningen (2009) 0.75

Hematogenous dissemination of transitional cell carcinoma in the bladder to the prostate. Scand J Urol Nephrol (2003) 0.75

[In Process Citation]. Lakartidningen (2016) 0.75

Prognostic significance of chromosome aberrations in high-grade soft tissue sarcomas. J Clin Oncol (2005) 0.75

Rediversion after urinary diversion: a single-centre experience. Scand J Urol (2013) 0.75

[Orbital fractures in children require immediate intervention. Risk of permanent double vision]. Lakartidningen (2009) 0.75

[Trauma care in the Southern region scrutinized. Peer review system for better care]. Lakartidningen (2006) 0.75